JSM Hepatitis

Decrease in Alcohol Consumption Improves Survival in Hepatitis C Infected Heavy Drinkers: A Longitudinal Cohort Study

Research Article | Open Access | Volume 2 | Issue 1

  • 1. Michael E DeBakey Veterans Affairs Medical Center, USA
  • 2. Baylor College of Medicine, USA
+ Show More - Show Less
Corresponding Authors
Shahriar Tavakoli Tabasi, Staff physician MEDVAMC and assistant professor of medicine Baylor College of Medicine, 2002 Holcombe Blvd, 111PC, Houston, TX 77030, Tel: 713-794-5280; Fax: 713-794-7838

Background: Excessive alcohol consumption is common among patients with chronic hepatitis C and contributes to the progression of liver disease.

Aims: The objective of this study is to determine the effect of decrease in alcohol consumption on survival of patients with chronic hepatitis C and excessive drinking.

Methods: We conducted a retrospective cohort study of patients with excessive alcohol consumption enrolled in the hepatitis C clinic from August 15, 2000 through December 30, 2007 at the Veterans Affairs Medical Center in Houston. Survival was measured through August 30, 2011. Inclusion criteria consisted of hepatitis C infection and consumption of > 50 grams of alcohol per day, absence of complicated cirrhosis, and absence of malignant medical conditions. The primary outcome of the study was survival, analyzed by Cox proportional hazard model.

Results: Two hundred eighty patients were followed for a mean of 6.34 years (SD 2.94). One hundred twenty two patients (44%) continued to drink above the risky drinking threshold and hundred fifty eight patients (56%) decreased alcohol consumption after a median of 2.73 (interquartile range: 0.34-5.26) years. Sixty six patients died. In Cox proportional hazards model, risky drinking (HR 1.58; CI 1.10-2.28), cirrhosis at baseline (HR 4.11; CI 2.38-7.10), and presence of medical co-morbidities (HR 2.65: CI 1.53-4.60) were associated with death.

Conclusion: Cessation of, or decrease in, alcohol consumption improves survival in patients with chronic hepatitis C infection. 


Hepatitis C infection; Alcohol; Cirrhosis ;Heavy drinking ; AUDIT.


Tabasi ST, Ninan S (2017) Decrease in Alcohol Consumption Improves Survival in Hepatitis C Infected Heavy Drinkers: A Longitudinal Cohort Study. JSM Hepat 2(1): 1010.


More than 3 million Americans live with hepatitis C virus (HCV) infection, the most common cause of chronic hepatitis in the United States [1]. HCV infection can result in progressive liver fibrosis, cirrhosis of the liver, and hepatocellular carcinoma [2-3]. Alcohol consumption plays an important role in progression of HCV-related liver disease [4]. Excessive alcohol consumption by HCV-infected patients increases the rate of progression of fibrosis, and development of cirrhosis [5-8]. In addition, even moderate alcohol consumption may be associated with accelerated progression of liver disease among HCV-infected individuals [9-12]. Moreover, alcohol may increase HCV replication and decrease the response rate to antiviral treatment [13-15]. It is also recognized that excessive alcohol consumption is common among HCV-infected patients, especially those using department of veterans medical system [16]. Therefore, treatment of alcohol abuse and dependence has been recommended for patients with chronic HCV infection prior to starting antiviral therapy [17]. To date, however, no study has proven a survival benefit from interventions that decrease alcohol consumption in HCV-infected excessive drinkers. It is also not clear if patients with behavioral and medical co-morbid conditions, which are prevalent among HCV-infected subjects [18,19], and those with advanced liver fibrosis may benefit from such interventions.

We performed this study to evaluate the survival in a cohort of HCV-infected patients who were drinking excessively. We evaluated the survival, as well as survival free of complications of cirrhosis, in those who quit or significantly cut down on drinking, compared to those who continued risky drinking.



We conducted a retrospective cohort study of patients with chronic HCV infection and excessive drinking, aged 18–80 years, who were evaluated from 8/15/2000 through 12/30/2007 in the MEDVAMC hepatitis C clinic in Houston, Texas. We defined excessive drinking as an estimated average of more than 50 grams of alcohol intake on a daily basis at the time of the initial visit to hepatitis C clinic [20]. Exclusion criteria included patients with: (a) preexisting complicated cirrhosis prior to or on the date of the first visit to hepatitis C clinic; (b) hepatocellular carcinoma (patients with AFP values > 200 ng/ml were included in this category); (c) concomitant chronic hepatitis B infection, defined by positive hepatitis B surface antigenemia; (d) malignant medical conditions (excluding basal cell and squamous cell carcinoma of the skin, CLL and slowly progressive lymphomas, low grade/slowly progressive prostate cancer).

Definition of variables

Alcohol consumption was evaluated in each subject quantitatively, both the past and current use. During each visit to the hepatitis C clinic, patients were asked to quantify the daily and average weekly alcohol consumption. In addition, we reviewed alcohol screening data, which is part of the annual clinical reminders and has been widely implemented in the department of Veterans Affairs hospitals since 1997. The yearly data included CAGE questionnaire from 2000 through June 2003, and AUDIT-Consumption (AUDIT-C) data afterwards [22,23].

Three variables were used to evaluate the effect of alcohol on survival. Past use of alcohol was evaluated semi-quantitatively as the number of years subjects reported drinking on average 50 grams of alcohol (excessive drinking years). Excessive drinking at the time of initial visit to hepatitis C clinic (more than an average of 50 grams daily alcohol consumption) was an inclusion criteria. Time for effective decline in alcohol consumption was evaluated based on the date alcohol consumption fell below a threshold of 14 drinks per week for men and 7 drinks per week for women, or an AUDIT-C score of more than 3 for men and more than 2 for women (risky drinking) [24]. The date for cessation of risky drinking was the first date when subjects reported a decrease in alcohol intake below risky levels, and never exceeded that threshold during subsequent visits. An ordinal variable was constructed in 4 groups based on when patients stopped risky drinking; within 30 days from visiting HCV clinic (group 1), within 1 year from visiting HCV clinic (group 2), after one year from visiting HCV clinic (group 3), never (group 4). Since the effect of alcohol consumption on progression of liver disease is not expected to reverse immediately after cessation of drinking, we did not include this variable as a time-dependent variable.

Co-morbid medical conditions were defined as one of the following: (a) coronary artery disease with NYHA class III or IV angina, (b) heart failure NYHA class III and IV, (c) chronic obstructive pulmonary disease GOLD stage IV and GOLD stage III with functional capacity less than 4 MET, (d) uncontrolled diabetes with hemoglobin A1c > 9%, and (e) diabetic proliferative retinopathy.

Information regarding substance use was actively sought by interview and thorough review of medical records. Active substance use was considered present if patients used cocaine, benzodiazepines, opiates, barbiturates, amphetamines, or other illegal drugs of abuse, in the 6 months prior to visiting hepatitis C clinic. The use of opiates, methadone, benzodiazepines, and barbiturates were not included in this category if prescribed by a physician. Recreational use of cannabis was not considered as active substance use.

Patients were asked about past history of mental health disorders, suicidal ideation with/without plan, and any attempt at suicide. Patients completed a Zung self reported depression (SDS) questionnaire during the first visit to hepatitis C clinic [18,21]. Mental health disorders were considered active in any patient with a history of major depressive disorder, bipolar disorder, psychosis, suicide attempt, hospitalization for pervasive suicidal ideation, or a score of 60 or more on Zung depression screen.

Patients were not eligible for antiviral therapy if they had comorbid medical, substance use, or psychiatric conditions. Instead, these patients were referred for management of these conditions and were followed in hepatitis C clinic. If the co-morbid conditions improved, patients became eligible for treatment.

We considered patient to have cirrhosis of the liver at the time of first visit to hepatitis C clinic if: (a) a liver biopsy within 6 months of the initial visit, showed METAVIR stage 4 fibrosis, (b) laboratory data showed significant liver synthetic dysfunction in the absence of other etiologies (albumin < 3.2 mg/ml and International normalized ratio > 1.4), or (c) imaging studies showed a nodular or coarse liver texture with irregular borders plus evidence of portal hypertension (presence of esophageal varices, splenomegaly, and/or portal vein diameter of > 1.5 cm) [25]. We calculated the estimated duration of HCV infection based on the risk factors for hepatitis C infection, as previously described [26,27]. Chronic hepatitis B infection was defined as positive hepatitis B surface antigenemia.


The primary outcome was death of any cause. Secondary outcome was a composite outcome of development of complicated cirrhosis and/or death. Complications of cirrhosis included any of the following: variceal bleeding, prophylactic banding/sclerotherapy for high risk varices, ascites, hepatic encephalopathy, hepatocellular carcinoma, and/or undergoing liver transplantation. Subjects who had any of these outcomes were censored on that date. Other subjects were censored on the last date they had a visit to the VA hospital system or on August 30, 2011. Patients were considered lost to follow up if they did not have a visit to one of the VA health-care facilities after December 30th 2010. Survival analysis was completed on August 30, 2011. To evaluate for survival and development of complications of cirrhosis, electronic medical records were reviewed for visits to any Veterans Health Administration hospital nationwide.

Statistical methods

For primary analysis we compared the survival curves between those who quit risky drinking versus those who continued to drink above risky drinking threshold. We used Cox proportional hazards model to determine hazard ratio (HR) and 95% confidence intervals (CI) for the effect of independent variables of interest on survival. The primary independent variable of interest was the duration of risky drinking after initial visit to our clinic (groups 1-4). Other independent variables included in this model were age, number of years of heaving drinking above average of 50 grams alcohol daily, estimated duration of hepatitis C infection, presence/absence of active substance use disorder at the time of first visit, presence/ absence of active mental health disorder at the time of first visit, presence/absence of co-morbid medical conditions at the time of first visit, presence of cirrhosis at the time of first visit, receiving antiviral treatment for hepatitis C, and sustained viral response to HCV treatment. We then repeated the model for secondary composite outcome death and/or complicated cirrhosis. The proportionality assumption underlying the Cox proportional hazard was evaluated by means of Schoenfeld residuals.

To test for the possibility that patients who decreased alcohol consumptions may have been more likely to receive antiviral treatment, we performed sensitivity analysis. We repeated Cox proportional hazard regression by deleting all patients who had undergone treatment and achieved sustained viral response.

To determine the differences between those who continued to drink and those who quit risky drinking, we performed multiple regression analysis. The outcome in this model was the duration of risky drinking after visiting HCV clinic. The independent factors analyzed were age, race, total years of heavy drinking, presence/ absence of active mental health disorders, presence/absence of active substance use disorder, Zung SDS, risk factor for hepatitis C infection (substance use related vs. others), estimated duration of HCV infection, presence/absence of cirrhosis of the liver at baseline. We checked for normality using the Shapiro-Wilk normality test. We checked for the presence of multicollinearity by calculating variance inflation factor.

This study was approved by the institutional review board of the Baylor College of Medicine, Houston, Texas, and MEDVAMC research and development committee.


From August 15th 2000 through December 30th 2007 hepatitis C clinic in MEDVAMC evaluated 2866 unique patients for hepatitis C infection. Two hundred eighty three had excessive alcohol intake without complicated cirrhosis. One patient was excluded due to hepatitis B co-infection, and two patients were excluded due to the presence of malignancy. At the end, 280 patients were included in the study. Baseline characteristics are shown in Table 1.

Table 1: Patient characteristics




274 (98%)

6 (2%)

Age (mean, SD) 51.6 (5.5)


African American






149 (53%)

116 (41%)

8 (3%)




Risk factor for hepatitis C infection

Positive history of IDU and/or snorting cocaine

229 (82%)
Median estimated duration of hepatitis C infection 29 (25-75 percentile: 24- 33) years
Mean duration of history of excessive drinking 28.2 (SD 9.4) years

Past history of mental health disorder

Depression-related disorders

Bipolar mood disorder

Post-traumatic stress disorder and anxiety Organic/substance-induced mood disorders


93 (33%)






Zung self-reported depression score; mean (SD) 52.4 (12.7)
Active mental health problems at initial HCV visit 92 (32%)
Co-morbid medical conditions 46 (16%)
Active substance use disorder 37 (13%)
Cirrhosis at initial HCV clinic visit 34 (12%)
Antiviral treatment during follow up Sustained viral response

36 (13%)

12/36 (33%)


As outlined in Table 1, the majority of patients were men with a high prevalence of co-morbid medical, psychiatric, and substance use disorders. Thirty four patients (12%) had cirrhosis of the liver during initial evaluation.

Twenty one patients (7.5%) had no visits after December 30th 2010 and were considered lost to follow up.

The mean duration of follow up was 6.34 years (SD 2.94). One hundred twenty two patients continued to drink above the risky drinking threshold. One hundred fifty eight patients decreased alcohol intake below risky drinking threshold, after a mean duration of 3.20 years (SD 2.82) from the initial visit to hepatitis C clinic. The primary outcome was death from any cause which occurred in 66 patients (24%). The cause of death was related to liver disease in 22 cases, unknown in 20 cases, and unrelated to liver disease in 24 cases.

Secondary composite outcome of complicated cirrhosis and/or death occurred in 87 subjects, over a mean follow up of 4.09 years (SD 2.73). Complications of cirrhosis occurred in 49 patients (17%). Initial complication of cirrhosis was ascites in 24 patients, hepatocellular carcinoma in 16 patients, variceal bleeding in 7 patients, prophylactic ligation of varices in one patient, and hepatic encephalopathy in 2 patients. One of the patients initially diagnosed with ascites was later diagnosed with hepatocellular carcinoma, bringing the total number of diagnosed cases of hepatocellular carcinoma to 17.

In multivariate cox proportional hazard regression, stepwise delay in abstaining from risky drinking (analyzed in groups 1 through 4 as an ordinal variable) (HR 1.58; CI 1.10-2.28), cirrhosis of the liver at baseline (HR 4.11; CI 2.38-7.10), and presence of medical co-morbidities (HR 2.65: CI 1.53-4.60) were associated with mortality. Number of years of excessive drinking (prior to visiting HCV clinic) and receiving antiviral treatment for hepatitis C were associated with a non-significant trend towards decreasing and improving survival respectively (Table 2).

Table 2: Cox proportional hazards model for predictors of death.

Variable HR 95% CI
Age at initial visit 1.02 0.96-1.07
Duration of excessive alcohol intake prior to initial visit 1.03 0.99-1.06
Mental health co-morbidity 0.81 0.47-1.38
Substance use co-morbidity 1.01 0.47-2.16
Medical co-morbidity 2.65 1.53-4.59
HCV treatment 0.28 0.06-1.22
Sustained viral response 0.89 0.08-10.09
Cirrhosis at initial visit 4.11 2.38-7.10
Quit risky drinking (groups 1-4) 1.58 1.10-2.28

When the analysis was repeated, with death and/or complicated cirrhosis as the composite outcome, results remained mostly unchanged. However, the number of years of excessive drinking prior to visiting HCV clinic reached statistical significance in this analysis, and was inversely associated with survival (? = 0.05).

Sensitivity analysis confirmed the findings in the Cox proportional hazard. When patients who had sustained viral response were not included in the analysis of the primary outcome, results remained unchanged.

Multiple regression analysis showed that older patients and those with cirrhosis of the liver at baseline, were more likely to quit risky drinking (? = 0.027 and < 0.001 respectively). Race, total years of heavy drinking, presence/absence of active mental health disorders, presence/absence of active substance use disorder, Zung SDS, risk factor for hepatitis C infection (substance use related vs. others), and estimated duration of HCV infection were not predictive of early cessation/decrease in alcohol consumption


We have demonstrated that HCV-infected excessive drinkers were less likely to die, if they were to quit drinking, or decrease drinking below risky drinking threshold. In addition, we have demonstrated that the composite outcome of death and/or complicated cirrhosis is improved in those who decrease drinking below the risky drinking threshold. We have also demonstrated that in addition to continued drinking, cirrhosis of the liver and presence of co-morbid medical conditions predicts poor prognosis in these patients. Finally, we found that older patients and those with cirrhosis of the liver were more likely quit risky drinking.

In spite of its retrospective design our study has several methodological strengths. The loss to follow up, one of the main pitfalls of cohort studies, was only 7.5%, which is highly unlikely to affect the outcomes of our study [28]. Missing data were negligible owing to availability of nation-wide reliable electronic medical records. Potential for exposure misclassification was not significant since alcohol use has been assessed by mandatory computer-generated clinical reminders in the department of Veterans Affairs hospitals on a yearly basis, since 1997 [22]. The risk for outcome misclassification was minimized due to the presence of detailed medical records and choice of well-defined objective outcomes. However, there were limitations to our study. The great majority of our subjects were men, limiting the external validity of our results for generalization to populations of HCV-infected women. The role of liver biopsy at baseline, close to initial HCV clinic visit, could not be evaluated since most patients did not have a liver biopsy then. However, if the improved outcome in those who quit risky drinking were because they had less severe liver fibrosis, we would have expected to see a reverse associated between cirrhosis of the liver and quitting risky drinking. On the contrary, we found that patients who quit earlier were more likely to have cirrhosis of the liver. Therefore, it is unlikely that such a phenomenon could explain the difference in survival observed in our study.

Our study demonstrates that HCV-infected patients with excessive drinking will significantly improve their prognosis if they quit risky drinking. Experts have widely recommended cessation of alcohol intake for HCV-infected patients based on indirect evidence that shows rapid progression of liver disease and higher incidence of cirrhosis in HCV-infected drinkers [5-8]. However, there has been little direct evidence to suggest that prognosis will actually improve if these patients were to quit/ decrease alcohol consumption. Drumright et al. showed that transition from alcohol use to abstinence among HCV-infected patients was associated with a decrease in liver enzymes, but did not study the protective effect of abstinence on mortality or development of cirrhosis [29]. Serra et al., studied the effects of abstinence from alcohol in patients with alcoholic cirrhosis, 72 of whom also had HCV infection [30]. They showed that, among all patients with alcoholic cirrhosis, the cumulative survival in abstinent alcoholics was significantly different from that of alcoholics who maintained the same pattern of alcohol consumption. However, the study was not designed, or powered, to evaluate the effect of abstinence in the subgroup of patients with chronic hepatitis C.

We were concerned that the protective effect of decrease in alcohol consumption may not be evident in all HCV-infected heavy drinkers, especially those with co-morbid conditions such as substance use disorder. However, we showed that decrease alcohol intake is protective irrespective of the diagnosis of substance use, mental health disorders, and medical comorbidities. We also found that medical co-morbidities, as defined in our study, predicted poor prognosis independent of other factors. This finding was expected since by definition these patients mostly had serious end-organ disease.

Patients who quit/decrease drinking were different from others in terms of being more likely to have cirrhosis of the liver and being older. Previously it has been shown that the knowledge of liver disease encourages patients to quit drinking [31-33]. This suggests that educating HCV-infected patients about progression of liver disease and consequences of cirrhosis may serve as an important tool for encouraging heavy drinkers to quit/decrease alcohol consumption. In addition, the results of our study should provide further encouragement for HCV-infected drinkers to quit/decrease alcohol consumption.

In summary, this study shows that cessation/decrease in alcohol consumption in HCV-infected patients improves outcomes. The benefit seems to extend to all patients, irrespective of severity of liver disease and co-morbid conditions. Knowledge of severity of liver disease may be a strong motive for patients to limit alcohol consumption.


This work was conducted at, and was supported by, the Michael E DeBakey VA Medical Center, Houston, TX


Authors are not reporting any conflict of interest related to this study. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institute of Diabetes Digestive and Kidney Diseases.


1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhhert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States. Ann Int Med. 2006; 144:705-714.

2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterol. 2004; 127: S35-S50.

3. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liv Dis. 2005; 9: 383-398.

4. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001; 34: 730-739.

5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349: 825- 832.

6. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatol. 1998; 28: 805-809.

7. Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce L, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: Report from the Dionysos study. Gut. 1999; 44: 874-880.

8. Seeff LB, Hollinger FB, Alter HJ. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatol. 2001; 33: 455-463.

9. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatol. 1998; 27: 1730-1735.

10. Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepatitis. 2002; 9: 235- 241.

11. Hézode C, Lonjon I, Roudot-Thoraval F, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: A prospective study. Aliment Pharmacol Therapeut. 2003; 17: 1031-1037.

12. Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, Kennedy R, Hodaj E, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol. 2003; 38: 307-314.

13. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, MartinotPeignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatol. 1998; 27: 1717-1722.

14. Romero-Gomez M, Grande L, Nogales MC, Fernandez M, Chavez M, Castro M. Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis. 2001; 33: 698-702.

15. Mochida S, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcoholism: Clin Exper Res. 1996; 20: 371A-377A.

16. El-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterol. 2002; 123: 476-482.

17. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatol. 2009; 49: 1335-1374.

18. Tavakoli-Tabasi S, Rowan P, Abdul-Latif M, Kunik ME, El-Serag HB. Utility of a Depression score to predict candidacy for HCV therapy in veterans: a prospective longitudinal study. Alim Pharmacol Therapeut. 2005; 21: 235-242.

19. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol. 2004; 38: 530-534.

20. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349: 825- 832.

21. Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965; 12: 63-70.

22. Bradley KA, Williams EC, Achtmeyer CE, Volpp B, Collins BJ, PA-C, Kivlahan DR. Implementation of Evidence-based Alcohol Screening in the Veterans Health Administration. Am J Manag Care. 2006; 12: 597-606.

23. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med.1998; 158: 1789-1795.

24. Frank D, DeBenedetti AF, Volk RJ, Williams EC, Daniel R. Kivlahan DR, Bradley KA. Effectiveness of the AUDIT-C as a Screening Test for Alcohol Misuse in Three Race/Ethnic Groups. J Gen Intern Med. 2008; 23: 781-787.

25. Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Lijima H, et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis: a multicenter collaborative study. Intervirol. 2008; 51: 17-25.

26. Tavakoli-Tabasi S, Ninan S. Clinical significance of perihepatic lymphadenopathy in patients with chronic hepatitis C infection. Dig Dis Sci. 2011; 56: 2137-2144.

27. ArmstrongGL, Wasley A, Simard EP, McQuillanGM, KuhnerWL, AlterMJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144: 705-714.

28. Kristman V, Manno M, Côté P. Loss of follow-up in cohort studies: how much is too much? Eur J Epidemiol. 2004; 19: 751-760.

29. Drumright LN, Hagan H, Thomas DL, Latka MH, Golub ET, Garfein RS, et al. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol. 2011; 55: 45-52.

30. Serra MA, Escudero A, Rodríguez F, del Olmo JA, Rodrigo JM. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. J Clin Gastroenterol. 2003; 36: 170- 174.

31. McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction. 2001; 96: 1007-1014.

32. Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 2002; 97: 1289-1294. 33.Sladden TJ, Hickey AR, Dunn TM, Beard JR. Hepatitis C virus infection: impacts on behavior and lifestyle. Aust N Z J Public Health. 1998; 22: 509-511


 Tabasi ST, Ninan S (2017) Decrease in Alcohol Consumption Improves Survival in Hepatitis C Infected Heavy Drinkers: A Longitudinal Cohort Study. JSM Hepat 2(1): 1010

Received : 23 Sep 2017
Accepted : 16 Oct 2017
Published : 19 Oct 2017
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X